━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TECHNOLOGY TRANSFER PACKAGE
P-01 — GREEN
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

**ONE-LINE OPPORTUNITY**
Technology: Multi-segment CSF shunt with Bayesian occlusion prediction and pre-emptive flow redistribution maintaining dual safety invariants. Problem: Catheter obstruction causes 30-50% of shunt failures. $35-50K per revision surgery (SOURCE_DERIVED: HCUP/AHRQ)..

**BUYER PROBLEM**
Who: Shunt OEM (Medtronic, Integra, Sophysa)
Problem: Catheter obstruction causes 30-50% of shunt failures. $35-50K per revision surgery (SOURCE_DERIVED: HCUP/AHRQ).
Current solution: Single-segment programmable valve (Medtronic Strata) — reactive, not predictive
Why inadequate: Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

**PROPOSED TECHNOLOGY**
Multi-segment CSF shunt with Bayesian occlusion prediction and pre-emptive flow redistribution maintaining dual safety invariants

**WHY IT MAY MATTER**
Potential differentiation vs Single-segment programmable valve (Medtronic Strata) — reactive, not predictive: Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

**CURRENT BEST ALTERNATIVE**
Single-segment programmable valve (Medtronic Strata) — reactive, not predictive

**WHAT IS ACTUALLY DEMONSTRATED**
  COMPUTATIONALLY_SUPPORTED: ['T2-CONDITIONAL. svMultiPhysics 3D Navier-Stokes verified 1D model within 16% on candidate geometry (flow-rate proxy). 225 ablations confirmed rate-limiting as critical mechanism in 41/45 runs.']

**WHAT IS ONLY MODELLED**
  - 30% revision rate reduction
  - $124M/yr value
  - 24h survival (both designs fail ~14h)

**KNOWN FAILURES**
  - Strict dual-invariant FALSIFIED (peak 22>20 mmHg)
  - 24h survival not achieved
  - FDA nozzle benchmark 72% disagreement (different geometry, not P-01's)

**KEY DIFFERENTIATOR**
Potential differentiation vs Single-segment programmable valve (Medtronic Strata) — reactive, not predictive: Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

**REMAINING DECISIVE UNCERTAINTY**
Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

**DECISIVE EXPERIMENT**
Experiment: V0 bench prototype: 4-segment shunt + COTS sensors + Arduino. 30 obstruction scenarios. Measure multi vs single peak ICP.
Pass: Multi-segment peak ICP < single-segment in >=80% of scenarios
Fail: Multi-segment shows no advantage over single-segment
Cost: $3-5K (ESTIMATED: COTS components)
Timeline: 3-6 months (ESTIMATED)

**BUILD / INTEGRATION PATH**
HIGH burden — requires multi-segment catheter + flow sensor (not commercially available)

**REGULATORY STATUS**
PMA required (Class III implantable)

**IP / DILIGENCE STATUS**
Known IP: BUYER_DILIGENCE_REQUIRED — no patent search performed for this package
Diligence required: Full freedom-to-operate analysis by buyer counsel

**COMMERCIAL ROUTES**
License to shunt OEM
(Options: LICENSE | BUILD | ACQUIRE | CO-DEVELOP | COMMISSION_EXPERIMENT | INTEGRATE | REJECT)

**BUYER'S NEXT ACTION**
LICENSE — reproduce computation (clone, run svMultiPhysics), then commission V0 bench prototype

**EVIDENCE MANIFEST**
Evidence ledger hash: 27bbdcc4fe5a009a...
BUYER_ACTION_ID: P01-EXP-001

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━